Niranjan Meher

Niranjan Meher

Auto-generated profile, based on publicly available information

Niranjan Meher

Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow, UP 226002, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
PGPeddaboodi Gopikrishna
Peddaboodi Gopikrishna
NMNiranjan Meher
Niranjan Meher
PIParameswar Krishnan Iyer
Parameswar Krishnan Iyer

6 April 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
NMNiranjan Meher
Niranjan Meher
SPSwagatika Panda
Swagatika Panda
SKSachin Kumar
Sachin Kumar
PIParameswar Krishnan Iyer
Parameswar Krishnan Iyer
Restriction of intramolecular motion (RIM) of rigid aromatic cores is the most universal mechanism so far that can successfully explain almost all AIE/AIEEgenic systems. By designing two novel naphthalimide derivatives (NIB and NIBD), we experimentally demonstrated the effect of a single formyl group that can efficiently transform an aggregation caused quenching (ACQ) system (NIB) into an AIEEgenic system (NIBD) by strengthening the RIM process. Besides, the newly designed naphthalimide AIEEgen (NIBD) accomplished ultrasensitive detection of hydrazine at the parts per trillion level (LOD/81 ppt) in aqueous media with high selectivity and enormous improvement over the existing state of the art. An exceptional sensitivity is also achieved in the vapor phase (LOD/0.003%) using a Whatman paper strip based portable device for simple and cost-effective on-site detection. The detection mechanism involved a reaction-based spontaneous formation of a non-fluorescent hydrazone Schiff base derivative (NIBDH). The in vitro potentiality of the AIEEgenic probe was also demonstrated in two mammalian cell lines i.e. HeLa (human cervical cancer cell line) and HEK293T (Human embryonic kidney cell line that expresses a mutant version of the SV40 large T antigen). Owing to the highly selective formation of the hydrazone Schiff base complex with hydrazine, NIBD responds to the existence of hydrazine in both these cell lines without any interference from other biologically rich metal ions and amino acids. These outcomes could initiate a much wider use of formyl group induced condensed state emission and a key hypothesis that could generate newer avenues for ACQ to AIEE transformations for several practical applications including hydrazone Schiff base complexation for probing and manipulating hydrazine biology associated with several metabolic activities.


17 June 2022 in Journal of Materials Chemistry C
Verified
Journal Article
Closed access
PDF file
NMNiranjan Meher
Niranjan Meher
DBDebasish Barman
Debasish Barman
RPRetwik Parui
Retwik Parui
PIParameswar Krishnan Iyer
Parameswar Krishnan Iyer
This review explores the up-to-date development of fluorescence-based detection of volatile organic contaminants (VOCs) on multiple platforms mainly highlighting mechanistic prospect that could help the future structural design of smart VOC sensors.

29 May 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
ATArvin Sain Tanwar
Arvin Sain Tanwar
NMNiranjan Meher
Niranjan Meher
LALaxmi Raman Adil
Laxmi Raman Adil
PIParameswar Krishnan Iyer
Parameswar Krishnan Iyer
In most of the sensing systems, specific detection mechanisms are involved during the detection process for a certain analyte irrespective of probes. However, unlike that of various sensing analytes, the detection of the highly toxic and explosive picric acid (PA) analyte was found to involve significant types of distinct sensing mechanisms depending on the nature of probes. Moreover, in the past five years, apart from the plethora of fluorescent probes designed, a number of unique organic small molecules and polymers have been strategically developed at our laboratory for the detection of PA, wherein the involvement of several diverse mechanisms along with a few new mechanisms depending on the electronic and photophysical properties of the probes has been unveiled. This involvement of several distinct mechanisms for the detection of PA motivated us to compile a step-by-step guide for the elucidation of the fluorescence sensing mechanism by taking PA as a model analyte. This “tutorial review” summarizes all the common sensing mechanisms involved for the detection of PA hitherto and provides a step-by-step guide to design experiments for the elucidation of sensing mechanisms for any newly designed sensing system. In addition to the appropriate classification of mechanisms involved for the fluorescence sensing of PA using various fluorescent systems developed at our laboratory, this tutorial review also includes most other possible mechanistic approaches studied previously. The present tutorial also provides a very unique method of a flow chart, which could help readers to elucidate the likely sensing mechanism via stepwise experimental and theoretical studies. Apart from the elucidation of the sensing mechanism for PA, this review presents an easy and distinct approach for the identification of all the involved mechanisms that would be of primary concern in the detection process of any analyte and could accurately help researchers in the easy and quick elucidation of sensing mechanisms in any kind of fluorophore-analyte system.

14 March 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ABAnil Bidkar
Anil Bidkar
SWSinan Wang
Sinan Wang
Kondapa Naidu BobbaKondapa Naidu Bobba
Kondapa Naidu Bobba
ECEmily Chan
Emily Chan
SBScott Bidlingmaier
Scott Bidlingmaier
RFRobert Flavell
Robert Flavell
Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody–drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46 epitope. Here, we present the preparation, preclinical efficacy, and toxicity evaluation of [225Ac]DOTA-YS5, a radioimmunotherapy agent based on the YS5 antibody. Experimental Design: [225Ac]DOTA-YS5 was developed, and its therapeutic efficiency was tested on cell-derived (22Rv1, DU145), and patient-derived (LTL-545, LTL484) prostate cancer xenograft models. Biodistribution studies were carried out on 22Rv1 tumor xenograft models to confirm the targeting efficacy. Toxicity analysis of the [225Ac]DOTA-YS5 was carried out on nu/nu mice to study short-term (acute) and long-term (chronic) toxicity. Results: Biodistribution study shows that [225Ac]DOTA-YS5 agent delivers high levels of radiation to the tumor tissue (11.64% ± 1.37%ID/g, 28.58% ± 10.88%ID/g, 29.35% ± 7.76%ID/g, and 31.78% ± 5.89%ID/g at 24, 96, 168, and 408 hours, respectively), compared with the healthy organs. [225Ac]DOTA-YS5 suppressed tumor size and prolonged survival in cell line–derived and patient-derived xenograft models. Toxicity analysis revealed that the 0.5 μCi activity levels showed toxicity to the kidneys, likely due to redistribution of daughter isotope 213Bi. Conclusions: [225Ac]DOTA-YS5 suppressed the growth of cell-derived and patient-derived xenografts, including prostate-specific membrane antigen–positive and prostate-specific membrane antigen–deficient models. Overall, this preclinical study confirms that [225Ac]DOTA-YS5 is a highly effective treatment and suggests feasibility for clinical translation of CD46-targeted radioligand therapy in prostate cancer.